<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="461">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584567</url>
  </required_header>
  <id_info>
    <org_study_id>UR17DN05</org_study_id>
    <nct_id>NCT04584567</nct_id>
  </id_info>
  <brief_title>OD-doxy-PNV-COVID-19 Old Drug &quot; DOXY &quot; for Prevention of New Virus &quot; COVID-19 &quot;</brief_title>
  <official_title>Covid-19 Infection Prophylaxis With Low Dose of Doxycycline and Zinc in Health Care Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hedi Gharsallah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dacima Consulting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General Administration of Military Health, Tunisia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the urgency of having guidelines for the management of COVID-19 in the current epidemic&#xD;
      context and the lack of specific pharmacological treatment, Military Health recommends the&#xD;
      launch of a multicenter, randomized, double-blind, interventional clinical trial.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy of a combination of two treatments,&#xD;
      low-dose doxcycline (100 mg/day) and Zinc (15 mg/day) (dietary supplement) in the primary&#xD;
      prevention of COVID-19 infection in health care professionals in Tunisia compared to two&#xD;
      control groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The participants who meeting study entry criteria will be randomized in a 1:1 blinded comparison of daily low dose DOXY versus oral placebo for 6 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>decreasing the number of cases infected with covid 19</measure>
    <time_frame>WEEK 6</time_frame>
    <description>Determine if the use of doxyciciline low dose as preventive treatment decrease the number of cases infected with covid 19 in the active arm compared to the placebo arm. Participants for each randomized treatment arm as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the emergence of clincal symptoms of COVID 19</measure>
    <time_frame>WEEK 6</time_frame>
    <description>Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the seroprevalence of SARS- CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving DOXY compared to those receiving placebo.</measure>
    <time_frame>WEEK 6</time_frame>
    <description>Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized DOXY versus placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>DOXY ZINC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOXY PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Doxycycline daily dosing (100mg) placebo of Zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of Doxycycline daily dosing placebo of Zinc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycyclin</intervention_name>
    <description>daily (100mg)</description>
    <arm_group_label>DOXY PLACEBO</arm_group_label>
    <arm_group_label>DOXY ZINC</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No self-medication with study drugs or antivirals&#xD;
&#xD;
          -  Negative COVID19 diagnosis confirmed by PCR and negative Elisa antibody assay&#xD;
&#xD;
          -  No signs of COVID19&#xD;
&#xD;
          -  Having given consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participation in other clinical trials aimed at primary prevention of VIDOC infection19&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Known allergy to the study product&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Vitamin A and E treatment in progress&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Batikh R Riadh, physican</last_name>
    <role>Study Chair</role>
    <affiliation>Military hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stambouli N nejla, phd</last_name>
    <role>Study Director</role>
    <affiliation>Military hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gharsallah H Hedi, physican</last_name>
    <role>Principal Investigator</role>
    <affiliation>Military hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferjani M Mustapha, physican</last_name>
    <role>Study Chair</role>
    <affiliation>Direction de la Sant√© militaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ben Moussa M mohamed, physican</last_name>
    <role>Study Chair</role>
    <affiliation>Military hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youssfi MA Mohamed Al, physican</last_name>
    <role>Study Chair</role>
    <affiliation>Military hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Batikh R Riadh, physican</last_name>
    <phone>55104234</phone>
    <phone_ext>216</phone_ext>
    <email>battikh.riadh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stambouli N nejla, phd</last_name>
    <phone>55104234</phone>
    <phone_ext>216</phone_ext>
    <email>nejlastam@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Military Hospital of Tunis</name>
      <address>
        <city>Tunis</city>
        <state>Montfleury</state>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedi Gharsallah, MD</last_name>
      <phone>71391885</phone>
      <phone_ext>00216</phone_ext>
      <email>gharsallahhedi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>najla stambouli, PhD</last_name>
      <phone>71391133</phone>
      <phone_ext>00216</phone_ext>
      <email>nejlastam@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Administration of Military Health, Tunisia</investigator_affiliation>
    <investigator_full_name>Hedi Gharsallah</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

